Nancy O'Hagan, CFCF Founder and President, wrote a new blog on remaining optimistic, positive, and united as a community. 

Dr. Matthew Kulke of the Dana Farber Cancer Institute and co-Chairman, CFCF Board of Scientific Advisors, wrote the inaugural entry highlighting recent progress in the field of neuroendocrine tumors research.  It is titled, "Neuroendocrine Tumors:  Progress at Last". 

"Neuroendocrine tumors present a paradox: while they are generally indolent in nature, they have historically been difficult to treat. While the inherent nature of these tumors may not be changing, the therapeutic options available to treat neuroendocrine malignancies are evolving more rapidly than at any time in the recorded past. In particular, "targeted" therapies hold promise for patients suffering from advanced disease. Advances in our basic understanding of neuroendocrine tumor biology, many of which have been supported by the Caring for Carcinoid Foundation, promise to yield additional information that will be useful in the development of novel treatments."

 

The Caring for Carcinoid Foundation (CFCF) is pleased to announce a partnership with Molecular Insight Pharmaceuticals Inc. in which both organizations will work together to improve the lives of carcinoid patients.

 

Molecular Insight Pharmaceuticals Inc. (MIP) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve patient healthcare by addressing significant unmet medical needs.  Molecular Insight Pharmaceuticals is committed to improving healthcare for patients with life-threatening diseases.

"The Caring for Carcinoid Foundation is grateful to MIP for their commitment to improving the lives of carcinoid patients as well as their commitment to advancing the field of carcinoid and related neuroendocrine tumor research," said Nancy O'Hagan, President and Founder of the Caring for Carcinoid Foundation.

 

"As a metastatic carcinoid patient, I am thrilled to see a company like MIP that is committed not only to improving patient health but also to partnering with non-profits like the Caring for Carcinoid Foundation, which is dedicated to discovering a cure for carcinoid cancer and devoting 100% of all donations to carcinoid and related neuroendocrine tumor research."

 

MIP will help to sponsor one of CFCF's 2008 scientific research grants.  Beyond this research partnership, MIP will sponsor CFCF's fundraisers to raise awareness of carcinoid and related neuroendocrine tumors, and help the carcinoid/related NET community raise much-needed funds for even more scientific research.  MIP will also sponsor Team Caring for Carcinoid Foundation in the following events:

Patients, family, and friends, please JOIN US!

 

For more information about participating in Team Caring for Carcinoid Foundation events--a fast, fun and easy way to raise money for carcinoid and related neuroendocrine tumor research--please visit:

Caring for Carcinoid Foundation Fundraising Events 

About Molecular Insight Pharmaceuticals (MIP)

MIP is a leader in the development of radiotherapeutics and molecular imaging pharmaceuticals.  MIP's proprietary Ultratrace technology allows creation of  radiopharmaceuticals with enhanced delivery and reduced side-effect profiles.   MIP currently has two therapies in clinical development for neuroendocrine tumors, Azedra and Onalta.  Azedra is planned to be marketed for the treatment of metastatic neuroendocrine tumors such as pheochromocytoma, carcinoid and neuroblastoma that are not amenable to treatment with surgery or conventional chemotherapy. Azedra has received Orphan Drug status and a Fast Track designation by the FDA.  Onalta is indicated for treatment of metastatic carcinoid and pancreatic neuroendocrine cancer in patients whose symptoms are not controlled by conventional somatostatin analog therapy.  Onalta has been granted Orphan Drug status by the FDA.  For more information about MIP, Azedra or Onalta please visit:

 

The runners made it look EASY.

 

THANK YOU, THANK YOU, THANK YOU for making the race a huge success - you helped raise over $8,500 for cancer research that WILL lead to a cure!!!!

 

Brimming with gratitude for your friendship,

Lance & Keri"

 

 

The Marine Corps Marathon is the largest marathon in the world that does not offer prize money, earning its nickname, "The People's Marathon."  The beautiful scenic course runs through the nation's capital and is nicknamed, "The Marathon of the Monuments."

 

Every dollar will directly fund cutting-edge carcinoid research.

 

For more information, please e-mail Team CFCF captain, Ryan Erb at:

 

 

Visit Team CFCF page

* No Federal or Marine Corps endorsement applied

Team Caring for Carcinoid Foundation (CFCF) proudly enters a team in the annual Bank of America Chicago Marathon on October 12, 2008.

100% of every dollar goes to cutting-edge carcinoid research.

Please support Team CFCF's runners including: